Wells Fargo Maintains Equal-Weight on Viridian Therapeutics, Lowers Price Target to $20

Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Equal-Weight and lowers the price target from $29 to $20.